Due to the critical role of HER2 in breast cancer tumor progression and response to treatment, the inhibition or depletion of SORL1 is a potential therapeutic strategy for increasing the drug sensitivity of breast cancer cells [8]. Here, ERBB2 is linked to breast carcinoma.